Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis

Objectives: To evaluate the impact of anti-tumour necrosis factor (TNF) treatment on growth and to identify the predictors for the change in growth in severe juvenile idiopathic arthritis (JIA). Methods: Data from 71 JIA patients (43 on etanercept, 28 on infliximab) were reviewed two years before an...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2006-08, Vol.65 (8), p.1044-1049
Main Authors: Tynjälä, P, Lahdenne, P, Vähäsalo, P, Kautiainen, H, Honkanen, V
Format: Article
Language:English
Subjects:
Adolescent
Age
anti-TNF treatment
Antibodies, Monoclonal - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis
Arthritis, Juvenile - drug therapy
Arthritis, Juvenile - immunology
Arthritis, Juvenile - physiopathology
Biological products
Blood Sedimentation
Body Height - drug effects
Body Mass Index
Body Weight - drug effects
C-Reactive Protein - analysis
Chi-Square Distribution
Child
Cytokines
Drug dosages
Etanercept
Extended Report
Female
Gangrene
growth
Growth - drug effects
Growth hormones
height standard deviation score
HSDS
Humans
ILAR
Immunoglobulin G - therapeutic use
Infliximab
International League of Associations for Rheumatology
JIA
juvenile idiopathic arthritis
Male
Methotrexate - therapeutic use
Patients
Prospective Studies
Receptors, Tumor Necrosis Factor - therapeutic use
Retrospective Studies
Standard deviation
Substance abuse treatment
TNF
TNF inhibitors
Treatment Outcome
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor necrosis factor-TNF
tumour necrosis factor
Velocity
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives: To evaluate the impact of anti-tumour necrosis factor (TNF) treatment on growth and to identify the predictors for the change in growth in severe juvenile idiopathic arthritis (JIA). Methods: Data from 71 JIA patients (43 on etanercept, 28 on infliximab) were reviewed two years before and two years on the anti-TNF treatment. The patients had polyarticular disease course (48 polyarthritis, 19 extended oligoarthritis, two systemic arthritis, and two enthesitis related arthritis). At the initiation of the anti-TNF treatment, their mean age was 9.6 years and the mean duration of JIA, 5.7 years. Results: In the patients with delayed growth before anti-TNF treatment (n = 53), the growth velocity, measured as the change in height standard deviation score, accelerated +0.45 (95% confidence interval, 0.33 to 0.56) (p
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.2005.047225